MCC-950 was originally found to act as a cytokine release inhibitory drug (CRID), arresting activated monocytes and preventing activation of caspase-11. Discovered to be a novel inhibitor of the NLRP3 and AIM2 inflammasomes2. Blocks canonical and noncano
* VAT and and shipping costs not included. Errors and price changes excepted